Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visual prognosis in giant cell arteritis

P D Aiello1, J C Trautmann, T J McPhee

  • 1Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905.

Ophthalmology
|April 1, 1993
PubMed
Summary

Giant cell arteritis (GCA) rarely causes vision loss after glucocorticoid therapy begins. Most visual deficits in GCA patients occur before treatment, with a low probability of further loss after therapy initiation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standard Versus Robot-Assisted Laparoscopic Hysterectomy: A Prospective Randomized Trial.

Journal of minimally invasive gynecology·2016
Same author

Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial.

Human reproduction (Oxford, England)·2013
Same author

Handling ability of gaseous microemboli of two pediatric arterial filters in a simulated CPB model.

Perfusion·2013
Same author

Hemodynamic evaluation of arterial and venous cannulae performance in a simulated neonatal extracorporeal life support circuit.

Perfusion·2011
Same author

Prominent perivascular enhancement in primary central nervous system vasculitis.

Clinical and experimental rheumatology·2008
Same author

Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy.

Rheumatology (Oxford, England)·2008

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Internal Medicine

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis that can lead to irreversible vision loss.
  • Early diagnosis and treatment are crucial to prevent visual complications.

Purpose of the Study:

  • To evaluate the visual prognosis in patients diagnosed with giant cell arteritis over a 5-year period.
  • To determine the incidence and timing of visual loss in relation to glucocorticoid therapy initiation.

Main Methods:

  • Retrospective review of medical records for patients diagnosed with GCA at the Mayo Clinic.
  • Follow-up data collected 5 years after initial diagnosis to assess visual status.

Main Results:

  • Out of 245 patients, 34 (14%) experienced permanent vision loss due to GCA.

Related Experiment Videos

  • Visual deficit occurred before glucocorticoid therapy in 32 patients.
  • The probability of vision loss developing after initiating glucocorticoid treatment was 1%; additional loss was 13% in those with pre-existing deficits.

    • Conclusions:

    • The development or progression of visual loss is infrequent after the initiation of glucocorticoid therapy for GCA.
    • Prompt treatment with glucocorticoids is effective in preserving vision in most GCA patients.